EntreMed: Corporate Presentation (Entremed) - Jan 24, 2014 - "Phase 1 Data Demonstrated Good Safety Profile and Promising Preliminary Antitumor Activity in Multiple Types of Solid Tumors"; "Overall Response Rate - PR: 3%, - SD: 85% (30% reduction in tumor size)"
P1 data • Breast Cancer • Oncology • Ovarian Cancer
|